BMS To Take Over Novartis Plant In Effort To Boost Viral Vector Production For CAR-Ts

 
• By Alaric DeArment

BMS’s myeloma CAR-T, Abecma, has faced manufacturing backlogs, like its rival, J&J and Legend Biotech’s Carvykti, with viral vector shortages playing a significant role.

BMS said it would take control of a Novartis plant in Illinois to manufacture viral vectors for CAR-T • Source: Shutterstock

More from Immuno-oncology

More from Anticancer